drugset / Trial / NCT01507064

Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma

NCT01507064 ↗

Phase 2 Completed 40 enrolled Cardarelli Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether neoadiuvant therapy with sorafenib increases the efficacy of thermal ablation in inducing the necrosis of hepatocellular carcinoma.

Timeline

Start
2012-01
Primary completion
2015-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 400 mg —